SAB Biotherapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for SAB Biotherapeutics, Inc. (SABS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-34.11-42.19-18.74-17.1420.12
Depreciation & Amortization4.793.753.291.650.55
Stock Based Compensation2.942.422.672.311.30
Change in Working Capital-2.303.65-0.248.36-11.95
Change in Accounts Receivable-0.055.562.4512.56-17.75
Change in Accounts Payable0.92-2.70-0.78-2.945.21
Change in Other Working Capital-3.173.71-1.812.060.48
Other Operating Activities-5.629.63-10.439.780.00
Net Cash from Operating Activities-34.29-25.12-23.461.9910.00
Investing Activities
Capital Expenditures-0.340.20-2.1710.94-12.73
Acquisitions0.000.000.0034.340.00
Purchases of Investments-37.450.000.000.000.00
Sales/Maturities of Investments25.820.000.000.000.00
Net Cash from Investing Activities-11.96-0.15-2.09-10.94-12.72
Financing Activities
Debt Repayment-0.91-0.13-2.42-1.30-1.58
Common Stock Issued0.0259.667.760.019.90
Common Stock Repurchased0.000.00-5.520.000.00
Other Financing Activities-0.29-1.03-5.52-0.020.00
Net Cash from Financing Activities-1.1766.771.0535.898.98
Summary
Effect of Forex Changes on Cash-0.240.020.000.000.00
Net Change in Cash-47.6741.50-24.5026.936.26
Cash at Beginning of Period56.5715.0539.5512.610.00
Cash at End of Period8.9098.7615.0539.550.00
Free Cash Flow-34.63-25.27-25.63-8.96-2.73
Supplemental Disclosures
Interest Paid0.370.250.290.290.00
Income Taxes Paid0.000.000.030.000.00